GlassScriptPhysician profile
Kristi Marie Toennies
NPI 1366467755
$8,950.30
in general payments reported to CMS, 2019-2025
53 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $1,977 · 2023: $1,638 · 2024: $2,297 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,539 · Education: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,538.68 |
| Education | $500.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $924.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $638.49 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $614.39 | 2021-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $593.15 | 2021-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $551.70 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Abbvie INC. | $495.31 | 2021-2025 | |
| Genzyme Corporation | $446.27 | 2021-2025 | |
| Incyte Corporation | $435.77 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Emd Serono, INC. | $334.08 | 2022-2025 | |
| Pfizer INC. | $262.79 | 2021-2025 | |
| Celgene Corporation | $236.97 | 2021-2025 | Reblozyl, Opdualag, Breyanzi |
| Seagen INC. | $231.93 | 2021-2023 | Padcev, Tukysa |
| Lilly USA, LLC | $225.71 | 2023-2025 | Jaypirca, Verzenio |
| Amgen INC. | $218.00 | 2021-2023 | Kyprolis, Nplate, Vectibix |
| Astrazeneca Pharmaceuticals LP | $215.54 | 2022-2025 | Imfinzi, Lynparza, Tagrisso |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Toennies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.